about
Management strategies for pancreatic pseudocystsControversies in the management of primary sclerosing cholangitisNovel endoscopic approaches in the diagnosis and management of biliary stricturesGuidelines for the diagnosis and treatment of cholangiocarcinoma: an updateSerum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitisTrial-based cost-effectiveness analysis comparing surgical and endoscopic drainage in patients with obstructive chronic pancreatitis.Photodynamic therapy using verteporfin photosensitization in the pancreas and surrounding tissues in the Syrian golden hamster.Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines.Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinomaUpdate on the management of cholangiocarcinoma.Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.Sociodemographic trends in the incidence of pancreatic and biliary tract cancer in UK primary care.Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma.CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy.A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancerDevelopment of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21.Gilbert's syndrome and the risk of death: a population-based cohort study.Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma.Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer.Systematic review of novel ablative methods in locally advanced pancreatic cancer.Photodynamic therapy for pancreatic carcinoma: experimental and clinical studies.Perfusion CT estimates photosensitizer uptake and biodistribution in a rabbit orthotopic pancreatic cancer model: a pilot study.Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.Biochemical markers of acute pancreatitis.Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor OutcomeIdentification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic AdenocarcinomaType 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohortBiomodulatory approaches to photodynamic therapy for solid tumorsPyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancerEndoscopic ultrasound of the upper gastrointestinal tract and mediastinum: diagnosis and therapy.Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experienceDiagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates.MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways.Genetic regulation of MUC1 alternative splicing in human tissuesGenetic factors in the pathogenesis of cholangiocarcinomaCdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpointEndoscopic versus percutaneous drainage of symptomatic pancreatic fluid collections: a 14-year experience from a tertiary hepatobiliary centre.
P50
Q24185900-D1D85B18-2453-4EFE-B11F-5463440B80AAQ26765804-2AA8DD31-8D4B-415C-9528-2D393EC01B68Q26853187-5DA7103F-7E82-4C5A-96F5-108D4B60ADF9Q28273143-895CED5F-8679-48D1-9E0E-B62D4F1EABD3Q29994579-1239B0B9-107E-48DE-8352-C44A4BFD7EC9Q30547712-792B6E55-3FC7-4FD0-A02F-EFC4A63F385CQ30831143-784917C1-D39E-4471-9DA2-5ACD08E34B64Q34068126-93F459AF-BFF0-494C-B3BE-F33F7F78C3C2Q34102283-EAC4BE9C-3548-4FFA-9FEB-FEB64DC53163Q34153255-FD64D57E-6BE6-4EC5-88EC-D29B3AF22133Q34275247-9287E7BB-A18D-42B7-8751-C18605F7BA8DQ34277315-89332370-9A0F-4777-A761-B11E4EA83F8DQ34496924-65833B39-E27C-455B-AFEB-63CF4BD3D6F4Q34500485-BB3CCDA3-25C7-4797-8C67-D32EC7DAFE9AQ34573243-08796B52-A271-4C1D-A599-CAD5F6E9D68AQ34627921-274D7965-3171-44B7-A998-2654D7A0714BQ34652167-FDEA0A08-F7C8-4999-AC7C-4A3D3694C285Q35092711-B4A498DA-3233-4453-ABDB-D6E639A36E5EQ35102975-7922A595-947A-40BD-999B-7F026D727A11Q35113615-5970DA77-FFD5-4284-A6E4-E45A3CA3A802Q35210457-FF359216-148C-4FE4-9F36-541DF9F2D727Q35395758-50952756-F4A2-4451-86D7-998DA0335782Q35607681-A0B830FE-E214-4154-B6B5-BB4B7A3CD2D2Q35620650-E21703CF-3202-4245-BD42-DC59C1F2D9B9Q35769864-909BC3FE-8B8D-46F7-B794-6D8F251213DDQ35962134-C54A8998-1B20-433C-A1C8-A007080CE5EBQ35964357-D64109E7-7559-44AE-94E7-8C8E7B1FE32CQ36003561-52B4CB95-C608-4113-93CA-110DD09576FFQ36283013-D6005926-6616-4766-B046-5D86CDED0CB0Q36381459-02B1B8ED-77D8-4312-9380-53D0C26A060FQ36577719-D971EF39-D0AC-4993-8D3C-42FC5E2C4710Q36644248-E4478176-B5F9-4071-B032-6D9440FB60CAQ36667380-CF9B31BD-5F13-4E23-9E42-DB109A0F9F60Q36667483-C0798FE5-1184-4DFE-80B9-F65A26E1767BQ36763283-E5FC1D46-C8AC-4A5A-94D2-913E9222323BQ36767541-42531F32-8A16-4176-9A8D-1D85C6095A4AQ36882720-77FF9216-621A-4E81-9AE0-03C619C225CBQ36966040-9E8F5DEB-7AD3-4BA2-91B9-1F9D286BBCE5Q37109795-883B18CF-670A-4022-91FB-5D3885F31986Q37191519-5E08C21B-3E89-4221-BBDD-3CE95C6B9D54
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stephen P. Pereira
@ast
Stephen P. Pereira
@en
Stephen P. Pereira
@es
Stephen P. Pereira
@nl
Stephen P. Pereira
@sl
type
label
Stephen P. Pereira
@ast
Stephen P. Pereira
@en
Stephen P. Pereira
@es
Stephen P. Pereira
@nl
Stephen P. Pereira
@sl
altLabel
Stephen Pereira
@en
prefLabel
Stephen P. Pereira
@ast
Stephen P. Pereira
@en
Stephen P. Pereira
@es
Stephen P. Pereira
@nl
Stephen P. Pereira
@sl
P1053
C-5639-2009
P106
P1153
55944100900
P21
P31
P3829
P496
0000-0003-0821-1809